Nominee for US top doc grilled on political pressure

M. Wadman

DOI: https://doi.org/10.1038/nm0807-892

2007-08-01

Nature Network Boston

Abstract:

What problem does this paper attempt to address?

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Ketao Jin,Kuifeng He,Guangliang Li,Lisong Teng

DOI: https://doi.org/10.2217/pme.10.48

2010-01-01

Personalized Medicine

Abstract:It has long been observed that interpatient variability in response to anticancer drugs is associated with different outcomes. Oncologists continually hold the desire of matching the right therapeutic regimen with the right cancer patient, which is termed 'personalized cancer therapy'. Rapid advances in genetics, genomics and related technologies are promising a new era of personalized cancer therapy based on individual molecular biomarkers. However, these molecular predictors of tumor response are far from perfect. Because of the inherent limitations in the current approaches for anticancer drugs response prediction, the need for new techniques to predict tumor response to therapy is urgent. Using a patient-derived human tumor tissue (PDTT) xenograft model to predict tumor response to therapy might be an ideal candidate method to choose. This article provides an overview of the achievements and limitations of genetic, genomic and proteomic molecular markers for personalized cancer therapy, and further discusses the potentials of using a PDTT xenograft model as a candidate strategy for personalized cancer therapy.
Personalized Medicine: Recent Progress in Cancer Therapy

Valentina Gambardella,Noelia Tarazona,Juan Miguel Cejalvo,Pasquale Lombardi,Marisol Huerta,Susana Roselló,Tania Fleitas,Desamparados Roda,Andres Cervantes

DOI: https://doi.org/10.3390/cancers12041009

2020-04-19

Cancers

Abstract:Translational research has revolutionized how we develop new treatments for cancer patients. The change from an organ-centric concept guiding treatment choice towards deep molecular analysis, driving a personalized approach, is one of the most important advances of modern oncology. Several tools such as next generation sequencing and RNA sequencing have greatly improved the capacity to detect predictive and prognostic molecular alterations. Detection of gene mutations, amplifications, and fusions has therefore altered the history of several diseases in both a localized and metastatic setting. This shift in perspective, in which attention is focused on the specific molecular alterations of the tumor, has opened the door to personalized treatment. This situation is reflected in the increasing number of basket trials selecting specific molecular targets. Nonetheless, some weaknesses need to be addressed. The complexity of cancer cells enriched with concomitant molecular alterations complicates identification of the driver. Moreover, tumor heterogeneity could be responsible for the lack of benefit when targeted agents are used. In light of this, there is growing interest in the role of multidisciplinary committees or molecular tumor boards to try to enhance selection. The aim of this review is to critically analyze the evolution of cancer treatment towards a precision approach, underlining some recent successes and unexpected failures.

oncology
Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer

Rong Hu,Xiaowei Wang,Xianquan Zhan

DOI: https://doi.org/10.1186/1878-5085-4-2

IF: 6.5

2013-01-01

The EPMA Journal

Abstract:Cancer is a complex disease that causes the alterations in the levels of gene, RNA, protein and metabolite. With the development of genomics, transcriptomics, proteomics and metabolomic techniques, the characterisation of key mutations and molecular pathways responsible for tumour progression has led to the identification of a large number of potential targets. The increasing understanding of molecular carcinogenesis has begun to change paradigms in oncology from traditional single-factor strategy to multi-parameter systematic strategy. The therapeutic model of cancer has changed from adopting the general radiotherapy and chemotherapy to personalised strategy. The development of predictive, preventive and personalised medicine (PPPM) will allow prediction of response with substantially increased accuracy, stratification of particular patient groups and eventual personalisation of medicine. The PPPM will change the approach to tumour diseases from a systematic and comprehensive point of view in the future. Patients will be treated according to the specific molecular profiles that are found in the individual tumour tissue and preferentially with targeted substances, if available.
Multi-parameter Systematic Strategy Opinion That Predicts, Prevents, and Personalized Treats a Cancer

Xianquan Zhan,Rong Hu,Xiaowei Wang

DOI: https://doi.org/10.1186/1878-5085-5-s1-a25

2013-01-01

Translational Medicine

Abstract:Cancer is a complex whole-body disease that alters in the levels of gene, protein, and metabolite, and that involves multi-factors, multi-processes and multi-consequences. Individual variation is involved in each stage of prediction/prevention, early-stage diagnosis/therapy, and late-stage diagnosis/therapy. The development of omics and systems biology has promoted one to gradually change paradigms in oncology from traditional single factor strategy to multi-parameter systematic strategy. The therapeutic model of cancer has changed from the general radiotherapy and chemotherapy to personalized strategy. The development of PPPM will substantially change the understanding, prediction, prevention, and therapeutic model of cancer from a systematical and comprehensive point of view in the future.
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer

Monica Valente,Alessia Covre,Anna Maria Di Giacomo,Michele Maio

DOI: https://doi.org/10.1007/978-3-030-37482-2_50-1

2021-01-01

Abstract:Cancers of the liver, biliary tract, and pancreas are among the gravest and most challenging issues for medical oncologists, being substantially chemo-resistant malignancies. In spite of the increasing incidence of hepato-biliary and pancreatic cancers, the initial diagnosis is often delayed due to the lack of specificity of the accompanying clinical symptoms. Apart from surgery when feasible, and unlike other tumor types, medical therapy has yet to provide significant improvement in the management of the advanced disease; thus, a limited number of new therapeutic agents have been approved in recent years. Nevertheless, in this still highly unsatisfactory scenario, the advances in genome science and in molecular and immuno-biologic knowledge of cancer are translating in a therapeutic and diagnostic improvement. Indeed, a personalized medicine approach may increasingly help to identify the more promising and effective individualized treatments for patients with hepato-biliary and pancreatic malignancies.
Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Ketao Jin,Kuifeng He,Fei Teng,Na Han,Guangliang Li,Zhenzhen Xu,Lisong Teng

DOI: https://doi.org/10.2217/pme.10.81

2011-01-01

Personalized Medicine

Abstract:Interpatient variability in response to anticancer drugs is associated with different clinical outcomes, which is partially owing to the individual differences among patients. Many investigators have hoped that tumor heterogeneity would help to reveal the underlying mechanism of interpatient variability in response to anticancer therapy. Numerous studies have demonstrated the presence of intratumor heterogeneity and the heterogeneity in primary tumors and corresponding metastases in a wide range of tumors at different levels and have indicated that the heterogeneity might make sense as a potential determinant of anticancer therapy response. This article discusses tumor heterogeneity, focusing on the heterogeneity in primary tumors and corresponding metastases as well as the effect on anticancer therapy response. Furthermore, an idea of tumor-site-based personalized cancer therapy for patients with metastatic malignancies was hypothesized, and a strategy using a patient-derived tumor tissue xenograft model to realize this idea is also proposed in this article.
Personalised Medicine: Taking a New Look at the Patient

Marco Scutari

DOI: https://doi.org/10.48550/arXiv.1401.2649

2014-01-13

Abstract:Personalised medicine strives to identify the right treatment for the right patient at the right time, integrating different types of biological and environmental information. Such information come from a variety of sources: omics data (genomic, proteomic, metabolomic, etc.), live molecular diagnostics, and other established diagnostics routinely used by medical doctors. Integrating these different kinds of data, which are all high-dimensional, presents significant challenges in knowledge representation and subsequent reasoning. The ultimate goal of such a modelling effort is to elucidate the flow of information that links genes, protein signalling and other physiological responses to external stimuli such as environmental conditions or the progress of a disease.

Applications
Advances in Personalized Oncology

Hiba Mechahougui,James Gutmans,Gina Colarusso,Roumaïssa Gouasmi,Alex Friedlaender

DOI: https://doi.org/10.3390/cancers16162862

2024-08-18

Cancers

Abstract:Advances in next-generation sequencing (NGS) have catalyzed a paradigm shift in cancer treatment, steering the focus from conventional, organ-specific protocols to precision medicine. Emerging targeted therapies offer a cutting-edge approach to cancer treatment, while companion diagnostics play an essential role in aligning therapeutic choices with specific molecular changes identified through NGS. Despite these advances, interpreting the clinical implications of a rapidly expanding catalog of genetic mutations remains a challenge. The selection of therapies in the presence of multiple mutations requires careful clinical judgment, supported by quality-centric genomic testing that emphasizes actionable mutations. Molecular tumor boards can play an increasing role in assimilating genomic data into clinical trials, thereby refining personalized treatment approaches and improving patient outcomes.

oncology
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.

Sebastian Pirmann,Stefan Fröhling,E. Schaeffeler,Matthias Schwab,Daniel Hübschmann,Roman Tremmel

DOI: https://doi.org/10.1124/pharmrev.124.001049

2024-10-15

Pharmacological Reviews

Abstract:Precision cancer medicine is widely established, and numerous molecularly targeted drugs for various tumor entities are approved or in development. Personalized pharmacotherapy in oncology has so far been based primarily on tumor characteristics, e.g., somatic mutations. However, the response to drug treatment also depends on pharmacological processes summarized under the term ADME (absorption, distribution, metabolism, and excretion). Variations in ADME genes have been the subject of intensive research for more than five decades, considering individual patients' genetic makeup, referred to as pharmacogenomics (PGx). The combined impact of a patient's tumor and germline genome is only partially understood and often not adequately considered in cancer therapy. This may be attributed, in part, to the lack of methods for combined analysis of both data layers. Optimized personalized cancer therapies should, therefore, aim to integrate molecular information about the tumor and the germline, taking into account existing PGx guidelines for drug therapy. Moreover, such strategies should provide the opportunity to consider genetic variants of previously unknown functional significance. Bioinformatic analysis methods and corresponding algorithms for data interpretation need to be developed to consider PGx data in interdisciplinary molecular tumor boards, where cancer patients are discussed to provide evidence-based recommendations for clinical management based on individual tumor profiles. Significance Statement The era of personalized oncology has seen the emergence of drugs tailored to genetic variants associated with cancer biology. However, full potential of targeted therapy remains untapped due to the predominant focus on acquired tumor-specific alterations. Optimized cancer care must integrate tumor and patient genomes, guided by pharmacogenomic principles. An essential prerequisite for realizing truly personalized drug treatment of cancer patients is the development of bioinformatic tools for comprehensive analysis of all data layers generated in modern precision oncology programs.

Biology,Medicine
Precision Medicine: Steps along the Road to Combat Human Cancer

Samuel F. Nassar,Khadir Raddassi,Baljit Ubhi,Joseph Doktorski,Ahmad Abulaban

DOI: https://doi.org/10.3390/cells9092056

IF: 6

2020-09-09

Cells

Abstract:The diagnosis and treatment of diseases such as cancer is becoming more accurate and specialized with the advent of precision medicine techniques, research and treatments. Reaching down to the cellular and even sub-cellular level, diagnostic tests can pinpoint specific, individual information from each patient, and guide providers to a more accurate plan of treatment. With this advanced knowledge, researchers and providers can better gauge the effectiveness of drugs, radiation, and other therapies, which is bound to lead to a more accurate, if not more positive, prognosis. As precision medicine becomes more established, new techniques, equipment, materials and testing methods will be required. Herein, we will examine the recent innovations in assays, devices and software, along with next generation sequencing in genomics diagnostics which are in use or are being developed for personalized medicine. So as to avoid duplication and produce the fullest possible benefit, all involved must be strongly encouraged to collaborate, across national borders, public and private sectors, science, medicine and academia alike. In this paper we will offer recommendations for tools, research and development, along with ideas for implementation. We plan to begin with discussion of the lessons learned to date, and the current research on pharmacogenomics. Given the steady stream of advances in imaging mass spectrometry and nanoLC-MS/MS, and use of genomic, proteomic and metabolomics biomarkers to distinguish healthy tissue from diseased cells, there is great potential to utilize pharmacogenomics to tailor a drug or drugs to a particular cohort of patients. Such efforts very well may bring increased hope for small groups of non-responders and those who have demonstrated adverse reactions to current treatments.

cell biology
Personalized medicine: Clinical oncology on molecular view of treatment

Rafick Costa Dos Santos Da Silva,Nathalia de Andrade Simon,André Alves Dos Santos,Gabriel De Melo Olegário,Jayne Ferreira Da Silva,Naide Oliveira Sousa,Manuel Alvarez Troncoso Corbacho,Fabrício Freire de Melo

DOI: https://doi.org/10.5306/wjco.v15.i8.992

2024-08-24

Abstract:Cancer, the second leading global cause of death, impacts both physically and emotionally. Conventional treatments such as surgeries, chemotherapy, and radiotherapy have adverse effects, driving the need for more precise approaches. Precision medicine enables more targeted treatments. Genetic mapping, alongside other molecular biology approaches, identifies specific genes, contributing to accurate prognoses. The review addresses, in clinical use, a molecular perspective on treatment. Biomarkers like alpha-fetoprotein, beta-human chorionic gonadotropin, 5-hydroxyindoleacetic acid, programmed death-1, and cytotoxic T lymphocyte-associated protein 4 are explored, providing valuable information. Bioinformatics, with an emphasis on artificial intelligence, revolutionizes the analysis of biological data, offering more accurate diagnoses. Techniques like liquid biopsy are emphasized for early detection. Precision medicine guides therapeutic strategies based on the molecular characteristics of the tumor, as evidenced in the molecular subtypes of breast cancer. Classifications allow personalized treatments, highlighting the role of trastuzumab and endocrine therapies. Despite the benefits, challenges persist, including high costs, tumor heterogeneity, and ethical issues. Overcoming obstacles requires collaboration, ensuring that advances in molecular biology translate into accessible benefits for all.
Shifting the paradigm in personalized cancer care through next-generation therapeutics and computational pathology

Jorge S Reis-Filho,Maurizio Scaltriti,Ansh Kapil,Hadassah Sade,Susan Galbraith

DOI: https://doi.org/10.1002/1878-0261.13724

2024-08-30

Abstract:The incorporation of novel therapeutic agents such as antibody-drug conjugates, radio-conjugates, T-cell engagers, and chimeric antigen receptor cell therapies represents a paradigm shift in oncology. Cell-surface target quantification, quantitative assessment of receptor internalization, and changes in the tumor microenvironment (TME) are essential variables in the development of biomarkers for patient selection and therapeutic response. Assessing these parameters requires capabilities that transcend those of traditional biomarker approaches based on immunohistochemistry, in situ hybridization and/or sequencing assays. Computational pathology is emerging as a transformative solution in this new therapeutic landscape, enabling detailed assessment of not only target presence, expression levels, and intra-tumor distribution but also of additional phenotypic features of tumor cells and their surrounding TME. Here, we delineate the pivotal role of computational pathology in enhancing the efficacy and specificity of these advanced therapeutics, underscoring the integration of novel artificial intelligence models that promise to revolutionize biomarker discovery and drug development.
Personalized Medicine in Brain Tumors

Quintino Giorgio D’Alessandris,Martina Offi,Liverana Lauretti,Roberto Pallini,Quintino Giorgio D'Alessandris

DOI: https://doi.org/10.3390/jpm14040413

IF: 3.5083

2024-04-13

Journal of Personalized Medicine

Abstract:Personalizing clinical, diagnostic and therapeutic approaches in neuro-oncology is a huge challenge [...]

medicine, general & internal,health care sciences & services
Personalizing chemotherapy dosing using pharmacological methods

Jai N Patel,Apostolos Papachristos

DOI: https://doi.org/10.1007/s00280-015-2849-x

Abstract:Purpose: Given the toxic nature and narrow therapeutic index of traditional chemotherapeutics, better methods of dose and therapy selection are critical. Pharmacological methods, including pharmacogenomics and pharmacokinetics, offer a practical method to enrich drug exposure, reduce toxicity, and improve quality of life for patients. Methods: PubMed and key abstracts from the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR) were searched until July 2015 for clinical data relating to pharmacogenomic- and/or pharmacokinetic-guided dosing of anticancer drugs. Results: Based on the results returned from a thorough search of the literature and the plausibility of utilizing pharmacogenomic and/or pharmacokinetic methods to personalize chemotherapy dosing, we identified several chemotherapeutic agents with the potential for therapy individualization. We highlight the available data, clinical validity, and utility of using pharmacogenomics to personalize therapy for tamoxifen, 5-fluorouracil, mercaptopurine, and irinotecan, in addition to using pharmacokinetics to personalize dosing for 5-fluorouracil, busulfan, methotrexate, taxanes, and topotecan. Conclusion: A concerted effort should be made by researchers to further elucidate the role of pharmacological methods in personalizing chemotherapy dosing to optimize the risk-benefit profile. Clinicians should be aware of the clinical validity, utility, and availability of pharmacogenomic- and pharmacokinetic-guided therapies in clinical practice, to ultimately allow optimal dosing for each and every cancer patient.
[Release and metabolism of brain noradrenaline during experimental ischemia. Effect of glycerol treatment].

P. Beley,J. Bralet

Abstract:The release and catabolism of brain NA were studied after labelling of endogenous NA stores with 3H NA in rats submitted to cerebral ischemia by injecting calibrated microspheres into the internal carotid artery. Twenty four hours after embolization, both NA release and catabolism were found to be reduced. They were restored after treatment with hyperosmolar solution of glycerol.
Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy

Cigir Biray Avci,Bakiye Goker Bagca,Behrouz Shademan,Leila Sabour Takanlou,Maryam Sabour Takanlou,Alireza Nourazarian

DOI: https://doi.org/10.1007/s10142-024-01462-4

2024-10-06

Functional & Integrative Genomics

Abstract:This review analyzes the application of machine learning (ML) in oncological pharmacogenomics, focusing on customizing chemotherapy treatments. It explores how ML can analyze extensive genomic, proteomic, and other omics datasets to identify genetic patterns associated with drug responses. This, in turn, facilitates personalized therapies that are more effective and have fewer side effects. Recent studies have emphasized ML's revolutionary role of ML in personalized oncology treatment by identifying genetic variability and understanding cancer pharmacodynamics. Integrating ML with electronic health records and clinical data shows promise in refining chemotherapy recommendations by considering the complex influencing factors. Although standard chemotherapy depends on population-based doses and treatment regimens, customized techniques use genetic information to tailor treatments for specific patients, potentially enhancing efficacy and reducing adverse effects.However, challenges, such as model interpretability, data quality, transparency, ethical issues related to data privacy, and health disparities, remain. Machine learning has been used to transform oncological pharmacogenomics by enabling personalized chemotherapy treatments. This review highlights ML's potential of ML to enhance treatment effectiveness and minimize side effects through detailed genetic analysis. It also addresses ongoing challenges including improved model interpretability, data quality, and ethical considerations. The review concludes by emphasizing the importance of rigorous clinical trials and interdisciplinary collaboration in the ethical implementation of ML-driven personalized medicine, paving the way for improved outcomes in cancer patients and marking a new frontier in cancer treatment.

genetics & heredity
Towards AI-Based Precision Oncology: A Machine Learning Framework for Personalized Counterfactual Treatment Suggestions based on Multi-Omics Data

Manuel Schürch,Laura Boos,Viola Heinzelmann-Schwarz,Gabriele Gut,Michael Krauthammer,Andreas Wicki,Tumor Profiler Consortium

2024-02-19

Abstract:AI-driven precision oncology has the transformative potential to reshape cancer treatment by leveraging the power of AI models to analyze the interaction between complex patient characteristics and their corresponding treatment outcomes. New technological platforms have facilitated the timely acquisition of multimodal data on tumor biology at an unprecedented resolution, such as single-cell multi-omics data, making this quality and quantity of data available for data-driven improved clinical decision-making. In this work, we propose a modular machine learning framework designed for personalized counterfactual cancer treatment suggestions based on an ensemble of machine learning experts trained on diverse multi-omics technologies. These specialized counterfactual experts per technology are consistently aggregated into a more powerful expert with superior performance and can provide both confidence and an explanation of its decision. The framework is tailored to address critical challenges inherent in data-driven cancer research, including the high-dimensional nature of the data, and the presence of treatment assignment bias in the retrospective observational data. The framework is showcased through comprehensive demonstrations using data from in-vitro and in-vivo treatment responses from a cohort of patients with ovarian cancer. Our method aims to empower clinicians with a reality-centric decision-support tool including probabilistic treatment suggestions with calibrated confidence and personalized explanations for tailoring treatment strategies to multi-omics characteristics of individual cancer patients.

Quantitative Methods,Machine Learning
Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?

M Aldea,L Friboulet,S Apcher,F Jaulin,F Mosele,T Sourisseau,J-C Soria,S Nikolaev,F André,M. Aldea,L. Friboulet,S. Apcher,F. Jaulin,F. Mosele,T. Sourisseau,J.-C. Soria,S. Nikolaev,F. André

DOI: https://doi.org/10.1016/j.esmoop.2023.101642

IF: 6.883

2023-10-01

ESMO Open

Abstract:Precision medicine for cancer is rapidly moving to an approach that integrates multiple dimensions of the biology in order to model mechanisms of cancer progression in each patient. The discovery of multiple drivers per tumor challenges medical decision that faces several treatment options. Drug sensitivity depends on the actionability of the target, its clonal or subclonal origin and coexisting genomic alterations. Sequencing has revealed a large diversity of drivers emerging at treatment failure, which are potential targets for clinical trials or drug repurposing. To effectively prioritize therapies, it is essential to rank genomic alterations based on their proven actionability. Moving beyond primary drivers, the future of precision medicine necessitates acknowledging the intricate spatial and temporal heterogeneity inherent in cancer. The advent of abundant complex biological data will make artificial intelligence algorithms indispensable for thorough analysis. Here, we will discuss the advancements brought by the use of high-throughput genomics, the advantages and limitations of precision medicine studies and future perspectives in this field.

oncology
Radionecrosis or Tumor Recurrence after Radiation: Importance of Choice for HBO

W. Narożny,J. Kuczkowski,B. Mikaszewski

DOI: https://doi.org/10.1016/j.otohns.2007.01.030

2007-07-01

Abstract:
Personalized medicine in breast cancer: pharmacogenomics approaches

Shabnam Jeibouei,Mohammad Esmael Akbari,Alireza Kalbasi,Amir Reza Aref,Mohammad Ajoudanian,Alireza Rezvani,Hakimeh Zali

DOI: https://doi.org/10.2147/PGPM.S167886

2019-10-07

Pharmacogenomics and Personalized Medicine

Abstract:Shabnam Jeibouei, 1 Mohammad Esmael Akbari, 2 Alireza Kalbasi, 3 Amir Reza Aref, 4, 5 Mohammad Ajoudanian, 6 Alireza Rezvani, 7 Hakimeh Zali 8 1 Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 4 Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA; 5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 6 Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 7 Department of Hematology, Medical Oncology and Stem Cell Transplantation, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 8 Proteomics Research Centre, Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Breast cancer is the fifth cause of cancer death among women worldwide and represents a global health concern due to the lack of effective therapeutic regimens that could be applied to all disease groups. Nowadays, strategies based on pharmacogenomics constitute novel approaches that minimize toxicity while maximizing drug efficacy; this being of high importance in the oncology setting. Besides, genetic profiling of malignant tumors can lead to the development of targeted therapies to be included in effective drug regimens. Advances in molecular diagnostics have revealed that breast cancer is a multifaceted disease, characterized by inter-tumoral and intra-tumoral heterogeneity and, unlike the past, molecular classifications based on the expression of individual biomarkers have led to devising novel therapeutic strategies that improve patient survival. In this review, we report and discuss the molecular classification of breast cancer subtypes, the heterogeneity resource, and the advantages and disadvantages of current drug regimens with consideration of pharmacogenomics in response and resistance to treatment. Keywords: breast cancer, personalized medicine, biomarker, pharmacogenomics

pharmacology & pharmacy

Nominee for US top doc grilled on political pressure

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Personalized Medicine: Recent Progress in Cancer Therapy

Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer

Multi-parameter Systematic Strategy Opinion That Predicts, Prevents, and Personalized Treats a Cancer

Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Personalised Medicine: Taking a New Look at the Patient

Advances in Personalized Oncology

Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.

Precision Medicine: Steps along the Road to Combat Human Cancer

Personalized medicine: Clinical oncology on molecular view of treatment

Shifting the paradigm in personalized cancer care through next-generation therapeutics and computational pathology

Personalized Medicine in Brain Tumors

Personalizing chemotherapy dosing using pharmacological methods

[Release and metabolism of brain noradrenaline during experimental ischemia. Effect of glycerol treatment].

Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy

Towards AI-Based Precision Oncology: A Machine Learning Framework for Personalized Counterfactual Treatment Suggestions based on Multi-Omics Data

Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?

Radionecrosis or Tumor Recurrence after Radiation: Importance of Choice for HBO

Personalized medicine in breast cancer: pharmacogenomics approaches